ClinicalTrials.gg
RecruitingNCT07288151Updated May 26, 2026

MDMA-Assisted Massed Exposure Therapy for PTSD

A Phase 2 interventional study of 3,4-Methylenedioxymethamphetamine (MDMA) and Placebo in Post Traumatic Stress Disorder, sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Planned enrollment
Largest of 38
200 · median 25
Started
2026
with 2 others
Phase 2
28 of 38
10 open now
Primary completion
2030-01
later than 11 of 11 live
Registered
37th of 38
by date
Lead sponsor
2 of 38
Emory University

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 28 in phase 2, reaches primary completion later than 11 of the 11 other live ones, and was the 37th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the efficacy of 3,4-methylenedioxy-methamphetamine hydrochloride (MDMA) combined with Massed Prolonged Exposure (PE) therapy for the treatment of posttraumatic stress disorder (PTSD) in adult participants diagnosed with PTSD. This randomized, placebo-controlled trial will enroll 95 participants.

The main questions it aims to answer are:

  • Does the combination of PE + MDMA lead to greater reduction in PTSD symptom severity from pre-treatment to one-month follow-up compared to PE + placebo?
  • Does PE + MDMA improve response efficiency and durability of PTSD symptom improvement compared to PE + placebo?
  • Does MDMA + PE enhance extinction retention and reduce amygdala threat reactivity, and are these changes associated with improved PTSD outcomes?

Participants will:

  • Receive 10 sessions of Massed Prolonged Exposure therapy over two weeks
  • Be administered either 100 mg of MDMA or a placebo at Visit 2
  • Undergo blinded independent evaluator assessments using the Clinician-Administered PTSD Scale for DSM-5-R (CAPS-5-R) at the one-month posttreatment follow-up
Read the detailed description

Posttraumatic stress disorder (PTSD) affects many individuals, including military veterans and civilians exposed to trauma. While trauma-focused therapies like Prolonged Exposure (PE) are effective, many people do not fully recover, and current medications often have limited success.

This study will test whether combining PE therapy with a single dose of MDMA (a psychoactive drug) can improve PTSD treatment outcomes. Ninety-five participants with PTSD will be randomly assigned to receive either MDMA or a placebo during the second of ten PE therapy sessions, which are delivered over two weeks. Researchers will measure PTSD symptoms one month after treatment using a standardized interview.

The study will also explore how MDMA affects brain responses related to fear and emotional memory, which may help explain how it works. Early results from a pilot study suggest this combination may lead to large reductions in PTSD symptoms. This is the first clinical trial to formally test MDMA with PE therapy, and it may lead to new, more effective treatment options for PTSD.

03

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • MDMA
  • 3,4-Methylenedioxymethamphetamine
  • Massed prolonged exposure therapy
  • Pos traumatic stress disorder
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale for - Revised (CAPS-5-R).
  • Able to speak and read English (due to standardization of outcome measures).
  • Willing to sign a release for the investigators to communicate with their primary care or mental health providers if indicated.
  • Able to swallow pills.
  • Agree to have study visits video and/or audio recorded, including Experimental Session, assessments, and non-drug therapy sessions.
  • Willing to provide a contact (relative, spouse, close friend, or another support person) who is willing and able to be contacted by the investigators.
  • Agree to inform the investigators within 48 hours of any medical conditions and procedures.
  • If able to become pregnant, must have a negative pregnancy test before study entry, at study entry, and before the Medicine Session. Must agree to use adequate for a month before the Medicine session and through 10 days after the Medicine Session.
  • Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications before the Medicine Session, and not participating in any other interventional clinical trials during the duration of the study, are driven home or to a hotel after the Medicine Session, and commit to medication dosing, therapy, and study procedures

Exclusion criteria

Exclusion Criteria:

  • Are not able to give adequate .
  • Have previously participated in a Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored MDMA clinical trial.
  • Have any current problem which, in the opinion of the investigator or study physician, might interfere with participation.
  • Have to any ingredient of the Medicinal Product (IMP).
  • Upon review of medical or psychiatric history and psychiatric assessment, have any current or past diagnosis that would be considered a risk to participating in the study
  • Requires ongoing psychiatric medication use with certain exceptions. Individuals may decide to taper psychiatric medications under the guidance of their local provider.
  • Have a history of any medical condition that could make receiving MDMA dangerous because of increases in blood pressure and heart rate or any medical condition the study physician believes would pose a safety risk or interfere with the effects of the treatment. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism is exclusionary.
  • Have any unstable medical condition that would interfere with participation.
  • Have uncontrolled hypertension) documented on three separate occasions.
  • Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.
  • Have a history of ever having ventricular arrhythmia or any other abnormal heart rhythm that the study physician believes would pose a significant risk of participation.
  • Have an abnormal finding on
  • Have a history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long Syndrome).
  • Require the use of concomitant medications that could impact the effects or safety of MDMA during the Medicine Session.
  • Have symptomatic liver disease or significant liver enzyme elevations.
  • Have a history of hyponatremia or hyperthermia.
  • Weigh less than 48 kilograms (105 lbs.).
  • Are pregnant or nursing
  • Have engaged in ketamine-assisted therapy or used ketamine within 12 weeks of enrollment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    MDMA group

    Drug: 3,4-Methylenedioxymethamphetamine (MDMA) · Behavioral: Massed Prolonged Exposure (PE)

  • Placebo comparator
    Standard of Care

    Drug: Placebo · Behavioral: Massed Prolonged Exposure (PE)

Interventions

  • DrugN-Methyl-3,4-methylenedioxyamphetamineStudies of N-Methyl-3,4-methylenedioxyamphetamineN-Methyl-3,4-methylenedioxyamphetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MDMA is a synthetic compound, commonly administered as MDMA hydrochloride (HCl). The drug will be administered in 100mg doses for a single session on Visit 2 out of 10- day study sessions over 2 weeks. MDMA is administered orally in capsule form and is taken under supervision in a controlled, therapeutic environment

    Also known as: MDMA

  • DrugPlacebo

    Placebos will visually match the 3 MDMA capsules (40mg, 40mg, and 20mg).

  • BehavioralMassed Prolonged Exposure (PE)

    Massed exposure therapy will be conducted for 11 sessions, 10 daily sessions and an additional therapy session during V2. They will consist of repeated exposures to trauma memories (imaginal exposure) consistent with the manualized protocol for massed exposure therapy. Also consistent with this treatment manual, participants will listen to imaginal exposures outside of PE sessions for "homework."

06

What researchers measure

Primary outcomes

  1. Changes in PTSD symptoms measured by CAPS-5-R

    The CAPS-5-R is a structured clinical interview used to assess PTSD symptoms based on DSM-5 criteria. Each symptom is rated on frequency and intensity * Combined into a severity score per item * Total score reflects overall PTSD symptom severity

    Time frame: Baseline, 1 month post-treatment

Secondary outcomes

  1. Changes in PTSD symptoms measured by PCL-5

    The PCL-5 is a 20-item self-report questionnaire used to measure PTSD symptoms based on DSM-5 criteria. Participants rate how much they've been bothered by each symptom in relation to a specific traumatic event, using a scale from 0 ("Not at all") to 4 ("Extremely"). A total score of 33 or higher indicates clinically elevated PTSD symptoms

    Time frame: Baseline, 1 month post treatment

  2. Change in PHQ questionnaire scores

    The PHQ-9 is a questionnaire used to assess depression severity. Each of the 9 items is scored from 0 to 3, giving a total score between 0 and 27. Higher scores suggest more severe depressive symptoms.

    Time frame: Baseline, 1 month post-treatment

Other outcomes

  1. Changes in fMRI-based neural activation patterns

    Participants will view 15 blocks of fearful face stimuli and 15 blocks of neutral face stimuli, with emotion condition randomly interweaved. Within each block, 8 face stimuli will be presented for 500 ms each, followed by a 500 ms intertrial interval. Changes in fMRI-based neural activation patterns following MDMA-assisted massed exposure therapy will be reported.

    Time frame: Day 1 of treatment, Day 10 of treatment

  2. Changes in fear extinction retention

    This will be assessed via a Pavlovian fear conditioning/extinction paradigm in which colored shapes are presented visually and paired with a 250 millisecond air blast. Changes in fear extinction retention following MDMA-assisted massed exposure therapy will be reported

    Time frame: Day 4, Day 10 of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jan 2030, 42 months later.

Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's planned 42 months is close to that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 17, 2025
StartEst.
Jul 2026
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07288151
Lead sponsor
Emory University
Collaborators
United States Department of Defense
Responsible party
Jessica Maples-Keller (Associate Professor, Emory University) — Principal investigator
First posted
Dec 17, 2025
Start date
Jul 2026 (estimated)
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
May 26, 2026

Study contacts

Jessica Maples-Keller, PhD
Contact
patstudy@emory.edu
404-712-1035
Syreese Fuller
Contact
patstudy@emory.edu
Jessica Maples-Keller, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion